<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320099</url>
  </required_header>
  <id_info>
    <org_study_id>AOM04100</org_study_id>
    <secondary_id>P040421</secondary_id>
    <nct_id>NCT00320099</nct_id>
  </id_info>
  <brief_title>Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock</brief_title>
  <acronym>COIITSS</acronym>
  <official_title>Phase 3 Study of Corticotherapy (Hydrocortisone Alone Versus Hydrocortisone Plus Fludrocortisone) Versus Corticotherapy Plus Intensive Insulin Therapy for Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Versailles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Versailles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare, in adults with septic shock, the safety and efficacy of a
      combination of moderate doses of corticosteroids and intensive insulin therapy to that of
      moderate doses of corticosteroids. In addition, this study will compare the efficacy and
      safety of hydrocortisone alone versus hydrocortisone plus fludrocortisone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      Comparison, in patients with septic shock, of efficacy and safety of the combination of
      moderate doses of corticosteroids and intensive insulin therapy to that of moderate doses of
      corticosteroids; and of efficacy and safety of hydrocortisone alone versus hydrocortisone
      plus fludrocortisone Methods

      Study design :

      This is a multicenter, prospective, randomised trial on parallel groups

      Study treatments :

      Experimental arm A:

      A1=50 mg iv every 6 hours of hydrocortisone (hemisuccinate), 50µg through the nasogastric
      tube of 9 alpha fludrocortisone, for 7 days AND strict control of blood glucose levels with a
      target of 4,4 to 6 mmol/L using continuous iv infusion of insulin up to intensive care unit
      discharge.

      A2=50 mg iv every 6 hours of hydrocortisone (hemisuccinate) for 7 days AND strict control of
      blood glucose levels with a target of 4,4 to 6 mmol/L using continuous iv infusion of insulin
      up to intensive care unit discharge.

      Control arm B:

      B1:50 mg iv every 6 hours of hydrocortisone (hemisuccinate), 50µg through the nasogastric
      tube of 9 alpha fludrocortisone, for 7 days.

      B2:50 mg iv every 6 hours of hydrocortisone (hemisuccinate)for 7 days. Study Primary outcome
      : In-hospital mortality

      Sample size calculation :

      The expected in-hospital mortality rate in the control group is 50%. To detect an absolute
      reduction in in-hospital mortality rate of 12.5 %, that is 37.5% in the experimental arm
      versus 50% in the control arm, and considering risk alpha of 0,05 and a risk beta of 0,20,
      254 patients per treatment arms are needed, for a total of 508 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Day 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes :</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day and 180-day mortality.</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of life-supporting treatments (i.e. vasopressors and mechanical ventilation)</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolve multiple organ dysfunction, i.e. to obtain a SOFA score &lt; 8</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay.</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycaemic events (blood glucose &lt; 4 mmol/l) during insulin infusion</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle weakness at discharge from intensive care unit, 90-day and 180-day</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post traumatic stress disorders</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrocortisone and convention glycemic control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone and fludrocortisone and conventional glucose control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone and intensive insulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hydrocortisone, fludrocortisone and intensive insulin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human insulin</intervention_name>
    <description>intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocortisone</intervention_name>
    <description>50 mg as iv bolus every 6 hours for 7 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludrocortisone</intervention_name>
    <description>50 µg once a day via a nasogastric tube for seven days</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>hydrocortisone 50mg q6 for 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients admitted in intensive care units for septic shock and meeting all following
        criteria

          -  Proven infection

          -  Need for vasopressor to maintain systemic arterial tension above 90 mmHg

          -  Multiple organ dysfunction as defined by a SOFA score ³ 8.

          -  Need for treatment with moderate dose of corticosteroids

        Exclusion Criteria:

        One of the following :

          -  Pregnancy

          -  Less than 18 years old

          -  Moribund (i.e. expected to die on day of intensive care unit admission)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Djillali annane, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique Hôpitaux de Paris - University of Versailles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital central</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Delafontaine</name>
      <address>
        <city>Saint Denis</city>
        <zip>93</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>COIITSS Study Investigators, Annane D, Cariou A, Maxime V, Azoulay E, D'honneur G, Timsit JF, Cohen Y, Wolf M, Fartoukh M, Adrie C, Santré C, Bollaert PE, Mathonet A, Amathieu R, Tabah A, Clec'h C, Mayaux J, Lejeune J, Chevret S. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA. 2010 Jan 27;303(4):341-8. doi: 10.1001/jama.2010.2. Erratum in: JAMA. 2010 May 5;303(17):1698.</citation>
    <PMID>20103758</PMID>
  </results_reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>April 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <last_update_submitted>April 5, 2010</last_update_submitted>
  <last_update_submitted_qc>April 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Djillali Annane</name_title>
    <organization>AP-HP - University of Versailles SQY</organization>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>adrenal insufficiency</keyword>
  <keyword>glucose control</keyword>
  <keyword>mineralocorticoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

